MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis

Ponce, Cesar Cilento; Chauffaille, Maria de Lourdes Ferrari; Ihara, Sílvia Saiuli Miki; Silva, Maria Regina R.

doi:10.1016/j.leukres.2011.06.024

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunoexpression intensity was designated as negative, weak, moderate, or strong on a scale from 0 to 3 ( Table 1 B). A final score for latent TGF-β1 immunostaining was obtained by multiplying the two analyzed variables (positivity and intensity), the values of which ranged from 0 to 9s 21–23 ( Table 1 and Fig. 1 ).…”

Section: Methodsmentioning

confidence: 99%

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

Ponce

Chauffaille²,

Ihara

et al. 2014

Revista Brasileira de Hematologia e Hemoterapia

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow biopsies from patients with essential thrombocythemia and primary myelofibrosis.MethodsMicrovascular density was evaluated by immunohistochemical analysis and the expression of latent TGF-β1 in samples (100 megakaryocytes per bone marrow sample) from 18 essential thrombocythemia and 38 primary myelofibrosis (19 prefibrotic and 19 fibrotic) patients. Six bone marrow donor biopsies were used as controls. Fibrosis in the bone marrow biopsies was evaluated according to the European Consensus.ResultsThe average fibrosis grade differed between essential thrombocythemia and primary myelofibrosis groups when compared to the control group. Latent TGF-β1 expression differed significantly between the fibrotic primary myelofibrosis (PMF) group and the control group (p-value < 0.01). A high degree of neo-angiogenesis (demonstrated by analysis of CD34 expression) was detected in patients with myelofibrosis. There were correlations between latent TGF-β1 expression and microvascular density (r = 0.45; p-value < 0.0009) and between degree of microvascular density and fibrosis grade (r = 0.80; p-value < 0.0001). Remarkable differences for neo-angiogenesis were not observed between patients with essential thrombocythemia and controls.ConclusionAngiogenesis participates in the pathogenesis of primary myelofibrosis, in both the prefibrotic and fibrotic stages, while latent TGF-β is differentially expressed only in the prefibrotic stage.

show abstract

Section: Methodsmentioning

confidence: 99%

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

Ponce

Chauffaille²,

Ihara

et al. 2014

Revista Brasileira de Hematologia e Hemoterapia

Self Cite

View full text Add to dashboard Cite

show abstract

“…This ambiguity has stimulated efforts to search for more reliable methods for confirming a specific diagnosis. Among these efforts, differences in STAT5 phosphorylation levels or in the expression frequency of thrombopoietin receptor in megakaryocytes have been proposed as useful diagnostic tools [6,7].…”

Section: Introductionmentioning

confidence: 99%

Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34–microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia

et al. 2015

View full text Add to dashboard Cite

“…A análise das imunoexpressões de TGF-b1 ativo e TGF-β1 latente foram realizadas conforme método previamente descrito (Ponce et al, 2012;Ponce et al, 2014). Foram empregadas IgG policlonal de coelho anti-TGF-b1 ativo humano (Santa Cruz Biotech; SC-146) e IgG policlonal de cabra anti-peptídeo associado à latência (LAP) humana para TGF-β1 latente (R&D Systems; AF-246-NA).…”

Section: Imunoexpressões De Tgf-b1 Ativo E Tgf-β1 Latenteunclassified

Efeito de SMADs e de microRNAs na expressão gênica de TGF-β1 e seu papel na angiogênese em pacientes com mielofibrose e trombocitemia essencial

Nunes¹

View full text Add to dashboard Cite

Cause love's such an old fashioned word And love dares you to care for The people on the edge of the night And loves dares you to change our way of Caring about ourselves Queen (Under Pressure) disparidades encontradas nas correlações entre a expressão gênica de TGF-β1 e diferentes SMADs e miRNAs nos pacientes e controles poderiam indicar que a regulação da expressão gênica de TGF-β1 nas doenças estudadas seja distinta da apresentada nos indivíduos sem essas doenças.

show abstract

MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis

Cited by 6 publications

References 17 publications

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34–microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Efeito de SMADs e de microRNAs na expressão gênica de TGF-β1 e seu papel na angiogênese em pacientes com mielofibrose e trombocitemia essencial

Contact Info

Product

Resources

About